Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.